Druggable orthosteric and allosteric hot spots to target protein-protein interactions.
暂无分享,去创建一个
[1] Saraswathi Vishveshwara,et al. Oligomeric protein structure networks: insights into protein-protein interactions , 2005, BMC Bioinformatics.
[2] A. Levine,et al. One billion years of p53/p63/p73 evolution , 2009, Proceedings of the National Academy of Sciences.
[3] R. Nussinov,et al. Allostery: absence of a change in shape does not imply that allostery is not at play. , 2008, Journal of molecular biology.
[4] E. Pasquale,et al. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion , 2006, Journal of Cell Science.
[5] T. Selwood,et al. Allosteric Inhibition of Human Porphobilinogen Synthase* , 2009, The Journal of Biological Chemistry.
[6] Jesús Avila,et al. Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[7] T. Schwartz,et al. The minor binding pocket: a major player in 7TM receptor activation. , 2010, Trends in pharmacological sciences.
[8] Olivier Sperandio,et al. Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.
[9] O. Dym,et al. The modular architecture of protein-protein binding interfaces. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] L. Lopiano,et al. Binding of anti‐Parkinson's disease drugs to human serum albumin is allosterically modulated , 2010, IUBMB life.
[11] R. Nussinov,et al. Conformational ensembles, signal transduction and residue hot spots: application to drug discovery. , 2010, Current opinion in drug discovery & development.
[12] Giorgio Palù,et al. Disruption of protein–protein interactions: Towards new targets for chemotherapy , 2005, Journal of cellular physiology.
[13] C. Prives,et al. Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.
[14] Pedro A Fernandes,et al. Hot spots—A review of the protein–protein interface determinant amino‐acid residues , 2007, Proteins.
[15] A. Bogan,et al. Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.
[16] C. Mattos,et al. Allosteric modulation of Ras positions Q61 for a direct role in catalysis , 2010, Proceedings of the National Academy of Sciences.
[17] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[18] Jonathan C. Fuller,et al. Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.
[19] Ravi Salgia,et al. The role of ephrins and Eph receptors in cancer. , 2004, Cytokine & growth factor reviews.
[20] R. Abagyan,et al. Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition* , 2007, Journal of Biological Chemistry.
[21] Dima Kozakov,et al. Analysis of binding site hot spots on the surface of Ras GTPase. , 2011, Journal of molecular biology.
[22] Y. Pommier,et al. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. , 2005, Trends in pharmacological sciences.
[23] E. Pasquale,et al. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. , 2010, Biochemistry.
[24] C. Chennubhotla,et al. Markov propagation of allosteric effects in biomolecular systems: application to GroEL–GroES , 2006, Molecular systems biology.
[25] E. Ruoslahti,et al. An Eph receptor regulates integrin activity through R-Ras. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] Bernard R Brooks,et al. Allosteric transitions in biological nanomachines are described by robust normal modes of elastic networks. , 2009, Current protein & peptide science.
[27] J. Rhim,et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway , 2001, Nature Cell Biology.
[28] Jie Liang,et al. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. , 2004, Journal of molecular biology.
[29] A. Lavie,et al. A New Dimension to Ras Function: A Novel Role for Nucleotide-Free Ras in Class II Phosphatidylinositol 3-Kinase Beta (PI3KC2β) Regulation , 2012, PloS one.
[30] K. Aoki,et al. The Scaffold Protein Shoc2/SUR-8 Accelerates the Interaction of Ras and Raf* , 2010, The Journal of Biological Chemistry.
[31] J. Hepler,et al. RGS14 is a multifunctional scaffold that integrates G protein and Ras/Raf MAPkinase signalling pathways. , 2010, Cellular signalling.
[32] Joël Janin,et al. Protein modules and protein-protein interaction. Introduction. , 2002, Advances in protein chemistry.
[33] R. Nussinov,et al. Is allostery an intrinsic property of all dynamic proteins? , 2004, Proteins.
[34] Michelle R Arkin,et al. The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions. , 2009, Current opinion in chemical biology.
[35] D Reichmann,et al. Binding hot spots in the TEM1-BLIP interface in light of its modular architecture. , 2007, Journal of molecular biology.
[36] R. Nussinov,et al. Allostery and population shift in drug discovery. , 2010, Current opinion in pharmacology.
[37] A. Meola,et al. Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer , 2010, Journal of oncology.
[38] H. Hirai,et al. A novel putative tyrosine kinase receptor encoded by the eph gene. , 1987, Science.
[39] Takashi Kumasaka,et al. Structural Basis for Conformational Dynamics of GTP-bound Ras Protein* , 2010, The Journal of Biological Chemistry.
[40] P. Kuhn,et al. Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. , 2006, Structure.
[41] R. Nussinov,et al. The different ways through which specificity works in orthosteric and allosteric drugs. , 2012, Current pharmaceutical design.
[42] S. Vajda,et al. Anchor residues in protein-protein interactions. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Nussinov,et al. Protein–protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[44] Oz Sharabi,et al. What makes Ras an efficient molecular switch: a computational, biophysical, and structural study of Ras-GDP interactions with mutants of Raf. , 2010, Journal of molecular biology.
[45] Elena B. Pasquale,et al. Eph receptors and ephrins in cancer: bidirectional signalling and beyond , 2010, Nature Reviews Cancer.
[46] C. Der,et al. Ras history , 2010, Small GTPases.
[47] Olivier Sperandio,et al. Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments , 2008, The open biochemistry journal.
[48] T. Kenakin. Ligand Detection in the Allosteric World , 2010, Journal of biomolecular screening.
[49] T. Schwartz,et al. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? , 2007, Trends in pharmacological sciences.
[50] Carla Mattos,et al. A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.
[51] Ozlem Keskin,et al. Towards inferring time dimensionality in protein–protein interaction networks by integrating structures: the p53 example† †This article is part of a Molecular BioSystems themed issue on Computational and Systems Biology. , 2009, Molecular bioSystems.
[52] Elena B Pasquale,et al. An Ephrin Mimetic Peptide That Selectively Targets the EphA2 Receptor* , 2002, The Journal of Biological Chemistry.
[53] Christopher D. Thanos,et al. Hot-spot mimicry of a cytokine receptor by a small molecule , 2006, Proceedings of the National Academy of Sciences.
[54] C. Post,et al. Constraining binding hot spots: NMR and molecular dynamics simulations provide a structural explanation for enthalpy-entropy compensation in SH2-ligand binding. , 2010, Journal of the American Chemical Society.
[55] Doheon Lee,et al. A feature-based approach to modeling protein–protein interaction hot spots , 2009, Nucleic acids research.
[56] F. J. Luque,et al. Binding site detection and druggability index from first principles. , 2009, Journal of medicinal chemistry.
[57] Nobuyoshi Sugaya,et al. Assessing the druggability of protein-protein interactions by a supervised machine-learning method , 2009, BMC Bioinformatics.
[58] H. Xi,et al. Eph receptors and ephrins as targets for cancer therapy , 2012, Journal of cellular and molecular medicine.
[59] Cornel Catana,et al. Inhibition of protein–protein interactions: The discovery of druglike β‐catenin inhibitors by combining virtual and biophysical screening , 2006, Proteins.
[60] R. Nussinov,et al. Hot regions in protein--protein interactions: the organization and contribution of structurally conserved hot spot residues. , 2005, Journal of molecular biology.
[61] Y. Yoshikawa,et al. Solution Structure of the State 1 Conformer of GTP-bound H-Ras Protein and Distinct Dynamic Properties between the State 1 and State 2 Conformers* , 2011, The Journal of Biological Chemistry.
[62] Mitsutoshi Nakada,et al. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. , 2005, The American journal of pathology.
[63] Robert Tampé,et al. ABC proteins in antigen translocation and viral inhibition. , 2010, Nature chemical biology.
[64] R. Nussinov,et al. Protein–protein interactions: organization, cooperativity and mapping in a bottom-up Systems Biology approach , 2005, Physical biology.
[65] Ruth Nussinov,et al. Energetic determinants of protein binding specificity: Insights into protein interaction networks , 2009, Proteomics.
[66] Alan R. Fersht,et al. Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.
[67] N. Lin,et al. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. , 2013, Biochemical pharmacology.
[68] M. Karplus,et al. Allostery and cooperativity revisited , 2008, Protein science : a publication of the Protein Society.
[69] M. Stratton,et al. The cancer genome , 2009, Nature.
[70] R. Noberini,et al. Targeting Eph receptors with peptides and small molecules: progress and challenges. , 2012, Seminars in cell & developmental biology.
[71] Jin Chen,et al. Eph receptors and Ephrins in cancer: common themes and controversies. , 2008, Cancer research.
[72] L. Vassilev,et al. Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.
[73] J. Frisén,et al. Ephrins and Eph receptors in stem cells and cancer. , 2010, Current opinion in cell biology.
[74] Ozlem Keskin,et al. HotPoint: hot spot prediction server for protein interfaces , 2010, Nucleic Acids Res..
[75] C. Der,et al. Inhibition of Ras for cancer treatment: the search continues. , 2011, Future medicinal chemistry.
[76] R. Noberini,et al. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. , 2012, The Biochemical journal.
[77] R. Nussinov,et al. Multiple‐Targeting and Conformational Selection in the Estrogen Receptor: Computation and Experiment , 2011, Chemical Biology and Drug Design.
[78] G. Salvesen,et al. Emerging principles in protease-based drug discovery , 2010, Nature Reviews Drug Discovery.
[79] J. Matthews,et al. Protein-protein interactions in human disease. , 2005, Current opinion in structural biology.
[80] R. Nussinov,et al. The underappreciated role of allostery in the cellular network. , 2013, Annual review of biophysics.
[81] K. Garber. Of Ephs and ephrins: companies target guidance molecules in cancer. , 2010, Journal of the National Cancer Institute.
[82] K. Murai,et al. Targeting the EphA4 receptor in the nervous system with biologically active peptides , 2003, Molecular and Cellular Neuroscience.
[83] Joe W. Gray,et al. Restriction of Receptor Movement Alters Cellular Response: Physical Force Sensing by EphA2 , 2010, Science.
[84] C. Crews,et al. Identification and Characterization of a Peptidic Ligand for Ras , 2010, Chembiochem : a European journal of chemical biology.
[85] K. O'Byrne,et al. Receptor tyrosine kinases and their activation in melanoma , 2011, Pigment cell & melanoma research.
[86] Julie C. Mitchell,et al. KFC Server: interactive forecasting of protein interaction hot spots , 2008, Nucleic Acids Res..
[87] S. Saito,et al. Relation between the conformational heterogeneity and reaction cycle of Ras: molecular simulation of Ras. , 2010, Biophysical journal.
[88] Wolfgang Wenzel,et al. Probing hot spots on protein-protein interfaces with all-atom free-energy simulation. , 2009, The Journal of chemical physics.
[89] T. Blundell,et al. Structural biology and drug discovery of difficult targets: the limits of ligandability. , 2012, Chemistry & biology.
[90] D. Megías,et al. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. , 2012, Blood.
[91] R. Nussinov,et al. The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins , 2005, Physical biology.
[92] Ozlem Keskin,et al. Identification of computational hot spots in protein interfaces: combining solvent accessibility and inter-residue potentials improves the accuracy , 2009, Bioinform..
[93] R. Nussinov,et al. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? , 2008, Chemical reviews.
[94] Zhan Xiao,et al. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner , 2012, Cancer biology & therapy.
[95] Carlos J. Camacho,et al. ANCHOR: a web server and database for analysis of protein–protein interaction binding pockets for drug discovery , 2010, Nucleic Acids Res..
[96] Herren Wu,et al. Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. , 2011, Journal of molecular biology.
[97] X. Daura,et al. Assessing the structural conservation of protein pockets to study functional and allosteric sites: implications for drug discovery , 2010, BMC Structural Biology.
[98] F. Guerlesquin,et al. Protein–protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein , 2007, Proceedings of the National Academy of Sciences.
[99] Andrea Mozzarelli,et al. Exploring and exploiting allostery: Models, evolution, and drug targeting. , 2011, Biochimica et biophysica acta.
[100] A. del Sol,et al. Small‐world network approach to identify key residues in protein–protein interaction , 2004, Proteins.
[101] Michelle R. Arkin,et al. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.
[102] Gerhard Klebe,et al. Strategies to search and design stabilizers of protein–protein interactions: A feasibility study , 2007, Proteins.
[103] Salam A. Assi,et al. Presaging Critical Residues in Protein interfaces-Web Server (PCRPi-W): A Web Server to Chart Hot Spots in Protein Interfaces , 2010, PloS one.
[104] E. Pasquale,et al. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. , 2004, Cellular signalling.
[105] Jean Chmielewski,et al. Inhibiting protein-protein interactions using designed molecules. , 2005, Current opinion in structural biology.
[106] Laurie E. Grove,et al. Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.
[107] Gideon Schreiber,et al. Protein binding specificity versus promiscuity. , 2010, Current opinion in structural biology.
[108] Laurence J. Miller,et al. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.
[109] C. Mattos,et al. Shift in the equilibrium between on and off states of the allosteric switch in Ras-GppNHp affected by small molecules and bulk solvent composition. , 2012, Biochemistry.
[110] J. Andrew McCammon,et al. Mapping the Druggable Allosteric Space of G-Protein Coupled Receptors: a Fragment-Based Molecular Dynamics Approach , 2010, Chemical biology & drug design.
[111] Di Wu,et al. Prediction of protein interaction hot spots using rough set-based multiple criteria linear programming. , 2011, Journal of theoretical biology.
[112] Massimiliano Pontil,et al. Prediction of hot spot residues at protein-protein interfaces by combining machine learning and energy-based methods , 2009, BMC Bioinformatics.
[113] Colin Norman,et al. What Don't We Know? , 2005, Science.
[114] H. Wolfson,et al. Protein functional epitopes: hot spots, dynamics and combinatorial libraries. , 2001, Current opinion in structural biology.
[115] Richard S Larson,et al. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. , 2005, Current protein & peptide science.
[116] S. Koide,et al. Understanding mechanisms governing protein-protein interactions from synthetic binding interfaces. , 2008, Current opinion in structural biology.